Severe cutaneous adverse drug reactions: incidence, clinical characteristics, treatment, and outcome in pediatric patients
Issued Date
2025-09-01
Resource Type
ISSN
0125877X
eISSN
22288694
Scopus ID
2-s2.0-105020785916
Pubmed ID
38183639
Journal Title
Asian Pacific Journal of Allergy and Immunology
Volume
43
Issue
3
Start Page
550
End Page
559
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology Vol.43 No.3 (2025) , 550-559
Suggested Citation
Na Bangxang P., Wisuthsarewong W., Nitiyarom R. Severe cutaneous adverse drug reactions: incidence, clinical characteristics, treatment, and outcome in pediatric patients. Asian Pacific Journal of Allergy and Immunology Vol.43 No.3 (2025) , 550-559. 559. doi:10.12932/ap-200623-1640 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112986
Title
Severe cutaneous adverse drug reactions: incidence, clinical characteristics, treatment, and outcome in pediatric patients
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Severe cutaneous adverse drug reactions (SCARs) can cause significant morbidity and mortality. Clinical data regarding such conditions is still limited in the pediatric population. Objective: To investigate the incidence, clinical characteristics, treatment, and outcome of SCARs in Thai pediatric patients. Methods: This retrospective study enrolled 52 patients aged less than 18 years who were diagnosed with acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or SJS/TEN overlap during January 2005 to August 2021 at Siriraj Hospital. Results: SCARs were slightly more prevalent in females than in males (51.9% vs. 48.1%). Median age at diagnosis was 97 months, and median length of hospital stay was 11 days. DRESS, SJS, TEN, AGEP, and SJS/TEN overlap was found in 44.2%, 36.5%, 9.6%, 5.8%, and 3.8%, respectively. The most common etiologies were antimicrobial agents (40.3%) and anticonvulsants (35.5%). Target lesions, vesicobullous lesions, purpura, positive Nikolsky’s sign, and skin tenderness were significant in blistering SCARs. Hematologic (84.6%) and hepatic (65.5%) manifestations were common. Treatment varied according to the clinical features of each condition. Systemic corticosteroids showed some benefit in SJS/TEN. One patient diagnosed with TEN died for an overall SCARs mortality rate of 1.9%. Conclusion: The unique characteristics of SCARs described herein can lead to timely and accurate diagnosis and proper management.